Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Non-Current Deffered Revenue data on file, last reported at $3.0 million in Q2 2025.

• For the quarter ending Q2 2025, Non-Current Deffered Revenue fell 32.89% year-over-year to $3.0 million; the trailing twelve-month figure through Jun 2025 stood at $3.0 million (down 32.89% YoY), and the FY2024 full-year result was $3.0 million, down 39.24% from the prior year.
• Non-Current Deffered Revenue for Q2 2025 stood at $3.0 million, down from $3.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $33.2 million in Q2 2021 and bottomed at $3.0 million in Q2 2025.
• The 5-year median for Non-Current Deffered Revenue is $6.5 million (2023), against an average of $11.2 million.
• Peak annual rise in Non-Current Deffered Revenue reached 25.37% in 2021, while the deepest fall reached 99.84% in 2021.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $29.1 million in 2021, then slumped by 72.2% to $8.1 million in 2022, then slumped by 38.52% to $5.0 million in 2023, then plunged by 39.24% to $3.0 million in 2024, then fell by 1.46% to $3.0 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $3.0 million (Q2 2025), $3.0 million (Q4 2024), and $4.4 million (Q2 2024), per Business Quant data.

Peer Comparison